NewLink Genetics Surges 4% Following Ebola Contract News

Loading...
Loading...

NewLink Genetics Corporation NLNK and Merck & Co Inc MRK announced a contract for development of an ebola vaccine Monday.

According to the press release, the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has awarded NewLink Genetics' wholly-owned subsidiary, BioProtection Systems, as the prime contractor in a $30 million contract to support the manufacturing and development activities of its investigational rVSV-EBOV (Ebola) vaccine candidate, including clinical development through a new 330-person Phase Ib study.

The vaccine candidate was initially developed by the Public Health Agency of Canada (PHAC), and is now being developed under an exclusive licensing and collaboration agreement between NewLink Genetics and Merck. The rVSV-EBOV (Ebola) vaccine candidate is currently being evaluated in Phase I clinical studies in humans.

Merck & Co Inc traded at $59.88 in the pre-market, up 0.50 percent

NewLink Genetics Corporation traded at $41.75 in the pre-market, up 4.09 percent.

Posted In: NewsBiomedical Advanced Research and Development AuthorityDepartment of Health and Human Services
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...